These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31963648)

  • 1. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial.
    Han E; Lee YH; Lee BW; Kang ES; Cha BS
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31963648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
    Ito D; Shimizu S; Inoue K; Saito D; Yanagisawa M; Inukai K; Akiyama Y; Morimoto Y; Noda M; Shimada A
    Diabetes Care; 2017 Oct; 40(10):1364-1372. PubMed ID: 28751548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Chehrehgosha H; Sohrabi MR; Ismail-Beigi F; Malek M; Reza Babaei M; Zamani F; Ajdarkosh H; Khoonsari M; Fallah AE; Khamseh ME
    Diabetes Ther; 2021 Mar; 12(3):843-861. PubMed ID: 33586120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.
    Miyake T; Yoshida S; Furukawa S; Sakai T; Tada F; Senba H; Yamamoto S; Koizumi Y; Yoshida O; Hirooka M; Kumagi T; Niiya T; Miyaoka H; Masanori A; Matsuura B; Hiasa Y
    Open Med (Wars); 2018; 13():402-409. PubMed ID: 30234161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.
    Ito D; Shimizu S; Haisa A; Yanagisawa S; Inoue K; Saito D; Sumita T; Yanagisawa M; Uchida Y; Inukai K; Shimada A
    J Diabetes Investig; 2024 May; ():. PubMed ID: 38775319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.
    Koshizaka M; Ishikawa K; Ishibashi R; Takahashi S; Sakamoto K; Yokoh H; Baba Y; Ide S; Ide K; Ishikawa T; Onishi S; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Maezawa Y; Yokote K
    Diabetes Ther; 2021 Jan; 12(1):183-196. PubMed ID: 33098565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Yabiku K; Mutoh A; Miyagi K; Takasu N
    Clin Ther; 2017 Mar; 39(3):558-566. PubMed ID: 28185715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.
    Attaran F; Emami S; Sohrabi M; Malek M; Ajdarkosh H; Khoonsari M; Ismail-Beigi F; Khamseh ME
    BMC Gastroenterol; 2023 Sep; 23(1):327. PubMed ID: 37742004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.
    Tsukagoshi-Yamaguchi A; Koshizaka M; Ishibashi R; Ishikawa K; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Terayama R; Hattori A; Takemoto M; Ouchi Y; Maezawa Y; Yokote K;
    Pharmacotherapy; 2023 Dec; 43(12):1317-1326. PubMed ID: 37772313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
    Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
    BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
    Takahashi H; Kessoku T; Kawanaka M; Nonaka M; Hyogo H; Fujii H; Nakajima T; Imajo K; Tanaka K; Kubotsu Y; Isoda H; Oeda S; Kurai O; Yoneda M; Ono M; Kitajima Y; Tajiri R; Takamori A; Kawaguchi A; Aishima S; Kage M; Nakajima A; Eguchi Y; Anzai K
    Hepatol Commun; 2022 Jan; 6(1):120-132. PubMed ID: 34558835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
    Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
    Ozaki A; Yoneda M; Kessoku T; Iwaki M; Kobayashi T; Honda Y; Ogawa Y; Imajo K; Sakai E; Taguri M; Yamanaka T; Iwasaki T; Kurihashi T; Saito S; Nakajima A
    Contemp Clin Trials Commun; 2020 Mar; 17():100516. PubMed ID: 31956725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
    Yokono M; Takasu T; Hayashizaki Y; Mitsuoka K; Kihara R; Muramatsu Y; Miyoshi S; Tahara A; Kurosaki E; Li Q; Tomiyama H; Sasamata M; Shibasaki M; Uchiyama Y
    Eur J Pharmacol; 2014 Mar; 727():66-74. PubMed ID: 24486393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.
    Della Pepa G; Russo M; Vitale M; Carli F; Vetrani C; Masulli M; Riccardi G; Vaccaro O; Gastaldelli A; Rivellese AA; Bozzetto L
    Diabetes Res Clin Pract; 2021 Aug; 178():108984. PubMed ID: 34311022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
    Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
    Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial.
    Razavizade M; Jamali R; Arj A; Matini SM; Moraveji A; Taherkhani E
    Hepat Mon; 2013 May; 13(5):e9270. PubMed ID: 23930133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.